title: Description of time- and frequency- domain-based measures of heart rate variability in individuals taking antiarrhythmics, beta blockers, calcium channel blockers, and/or antihypertensive drugs after sudden cardiac arrest.
abstract: Concomitant drug therapies after sudden cardiac arrest and their potential effect of altering heart rate variability (HRV) represent confounding factors in interpreting the outcome of nonpharmacologic therapies on HRV. The purpose of this study is to describe a broad spectrum of time-domain and frequency-domain measurements of HRV in 50 individuals after sudden cardiac arrest. Some of the individuals were taking antiarrhythmics (n = 9), beta blockers (n = 13), calcium channel blockers (n = 10), nitrates (n = 8), cardiac glycosides (n = 10), and/or antihypertensives (n = 12). Heart rate variability was measured using a Holter recorder for 24 hours and the SpaceLabs FT2000 Monitoring System (Redmond, WA). In those individuals taking antiarrhythmic drugs, the power density within the low-frequency range (.016-.04 Hz) was significantly decreased (P = .001) compared to those not taking antiarrhythmics (n = 41). However, 78% of the people taking antiarrhythmics also had congestive heart failure (New York Heart Association functional classes II and III), which also decreased HRV. Those individuals taking beta blockers tended to have slower heart rates (P < .01). The association between beta blocker use and HRV was positive, but not statistically significant except for the increased power density in the low-frequency range (P < .05). In general, the relationships between HRV and drug therapy--calcium channel blockers, antihypertensives, cardiac glycosides, or nitrates--were not statistically significant.
authors.affiliation: Department of Physiological Nursing, School of Nursing, University of Washington, Seattle 98195.
authors.forename: M J
authors.initials: MJ
authors.lastname: Cowan
authors.forename: K
authors.initials: K
authors.lastname: Pike
authors.forename: R L
authors.initials: RL
authors.lastname: Burr
authors.forename: K C
authors.initials: KC
authors.lastname: Cain
authors.forename: S B
authors.initials: SB
authors.lastname: Narayanan
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002301:Cardiac Glycosides / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D015716:Electrocardiography, Ambulatory; D005260:Female; D006323:Heart Arrest / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D002301:Cardiac Glycosides; D002317:Cardiovascular Agents; D009566:Nitrates; D001241:Aspirin